Show simple item record

dc.contributor.authorReckamp, KL
dc.contributor.authorLin, HM
dc.contributor.authorCranmer, H
dc.contributor.authorWu, Y
dc.contributor.authorZhang, P
dc.contributor.authorWalton, LJ
dc.contributor.authorKay, S
dc.contributor.authorCichewicz, A
dc.contributor.authorNeupane, B
dc.contributor.authorFahrbach, K
dc.contributor.authorPopat, S
dc.contributor.authorCamidge, DR
dc.coverage.spatialEngland
dc.date.accessioned2022-08-11T11:12:02Z
dc.date.available2022-08-11T11:12:02Z
dc.date.issued2022-05-24
dc.identifier.citationFuture Oncology, 2022, 18 (20), pp. 2499 - 2510en_US
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5259
dc.identifier.eissn1744-8301
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2022-0194
dc.description.abstractAim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). Results: No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Conclusion: Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK-positive NSCLC.
dc.formatPrint-Electronic
dc.format.extent2499 - 2510
dc.languageeng
dc.language.isoengen_US
dc.publisherFUTURE MEDICINE LTDen_US
dc.relation.ispartofFuture Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectALK inhibitor
dc.subjectBucher ITC
dc.subjectNSCLC
dc.subjectalectinib
dc.subjectbrigatinib
dc.subjectmatching-adjusted indirect comparison
dc.subjectprogression-free survival
dc.subjectsystematic literature review
dc.subjectAnaplastic Lymphoma Kinase
dc.subjectCarbazoles
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectClinical Trials as Topic
dc.subjectCrizotinib
dc.subjectDisease Progression
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectOrganophosphorus Compounds
dc.subjectPiperidines
dc.subjectProtein Kinase Inhibitors
dc.subjectPyrimidines
dc.titleIndirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-04-27
dc.date.updated2022-08-11T11:10:59Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.2217/fon-2022-0194en_US
rioxxterms.licenseref.startdate2022-05-24
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35608148
pubs.issue20
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished
pubs.volume18
dc.contributor.icrauthorPopat, Sanjay
icr.provenanceDeposited by Mr Arek Surman on 2022-08-11. Deposit type is initial. No. of files: 1. Files: fon-2022-0194.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/